Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2016

Summary

‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2016,’ provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview
Therapeutics Development
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
Aeolus Pharmaceuticals, Inc.
Angion Biomedica Corp.
Atox Bio Inc.
Avaxia Biologics, Inc.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles

AB-103 - Drug Profile

ABC-294640 - Drug Profile

AEOL-10150 - Drug Profile

AEOL-10171 - Drug Profile

Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis - Drug Profile

AVMOC-001 - Drug Profile

AVX-470 - Drug Profile

BB-3 - Drug Profile

BBT-007 - Drug Profile

BBT-015 - Drug Profile

BBT-018 - Drug Profile

BBT-059 - Drug Profile

BCN-057 - Drug Profile

BIO-300 - Drug Profile

BMX-001 - Drug Profile

BPC-2 - Drug Profile

C-2E2 - Drug Profile

C-2E5 - Drug Profile

CBLB-613 - Drug Profile

CLT-009 - Drug Profile

EDL-2000 - Drug Profile

entolimod - Drug Profile

EWA-001 - Drug Profile

HSJ-0017 - Drug Profile

JP4-039 - Drug Profile

LGM-2605 - Drug Profile

LY-2109761 - Drug Profile

m2A2 - Drug Profile

NMIL-121 - Drug Profile

ondansetron hydrochloride - Drug Profile
ondansetron hydrochloride CR - Drug Profile
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
pirfenidone - Drug Profile
PLXR-18 - Drug Profile
PrC-210 - Drug Profile
RDD-2007 - Drug Profile
recilisib sodium - Drug Profile
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile
Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile
Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
RES-529 - Drug Profile
RP-239X - Drug Profile
rusalatide acetate - Drug Profile
Rx-100 - Drug Profile
RX-101 - Drug Profile
SGX-201 - Drug Profile
SGX-202 - Drug Profile
Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile
Small Molecules for Radiation and Chemical Toxicity - Drug Profile
Small Molecules for Radiation Toxicity - Drug Profile
Small Molecules to Activate Vitamin D Receptor for Radiation Injury - Drug Profile
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
ST-7 - Drug Profile
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
Stem Cell Therapy for Radiation Exposure - Drug Profile
SY-303A - Drug Profile
SY-513 - Drug Profile
SYGN-305P - Drug Profile
SYGN-399 - Drug Profile
Thrombosomes - Drug Profile
Products under Development by Companies, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Avaxia Biologics, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Caladrius Biosciences, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Eli Lilly and Company, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by INSYS Therapeutics, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corporation, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ProCertus BioPharm Inc., H1 2016
2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by StemEdica Cell Technologies, Inc., H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..3), H1 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2016

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3691135/](http://www.researchandmarkets.com/reports/3691135/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2016 |
| Web Address: http://www.researchandmarkets.com/reports/3691135/ |
| Office Code: SCD2AZ1Z |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>☐</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>☐</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - EnterpriseWide:</td>
<td>☐</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: _______________________
Email Address: * _______________________
Job Title: ____________________________
Organisation: _________________________
Address: _____________________________
City: ________________________________
Postal / Zip Code: ____________________
Country: _____________________________
Phone Number: _________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp